+
+
Stay Informed
TEER

MITRACLIP™ Transcatheter Edge-to-Edge Repair (TEER)

Uncompromising performance that sets the standard in mitral valve repair. With over 20 years of experience, extensive clinical evidence, and more than 200K patients treated worldwide.1

Control Meets Efficiency

G5 is the next evolution of the MitraClip TEER system offering easy handling, precise positioning, and intuitive deployment that enhances both control and efficiency, allowing you to focus on what matters most — your patients

 

Tests performed by and data on file at Abbott.

A better quality of life is possible for your patients with Mitral Regurgitation (MR)


The MitraClip G5 System is indicated for patients with symptomatic primary (degenerative) or secondary (functional) significant mitral regurgitation (MR ≥ 2+).

The catalyst for a significant evolution in MR guidelines

MitraClip is the first TEER (TMVr) therapy recommended by AHA/ACC/HFSA and ESC/EACTS guidelines and APSC recommendations for select primary and secondary MR patients.2-5,12

Severe MR is vastly undertreated

  • Surgical intervention not offered or denied
    Severe MR is vastly undertreated with no surgical intervention


    49% of patients with symptomatic severe MR were not operated due to age, co-morbidities, or impaired LV.6 If left untreated, MR initiates a cascade of events leading to death, with 1-year mortality up to 57%7

IDENTIFYING PATIENTS FOR MITRACLIP THERAPY


MitraClip Transesophageal Echo (TEE)
Screening Guide
 

DOWNLOAD NOW


MitraClip Procedural Positioning and Imaging Guide
 

DOWNLOAD NOW


MitraClip Transthoracic Echo (TTE)
Screening Guide
 

DOWNLOAD NOW

MitraClip G5 TEER System

MitraClip G5
1
2
3
4
5
  1. Guide Attach
  2. DS Attach
  3. DC Fastener
  4. Lock Line Release Latch
  5. Lock Line Release Slider

Delivery Catheter (DC) Handle

  • Handle has integrated gripper levers and reduced flush volume.

    • Arm Positioner

  • Hard stop within arm positioner in open direction.

    • Release Pin

  • Finger hold to pull and initiate clip deployment.

    • Lock Line Release Latch

  • Releases one end of lock line at time of deployment.

    • Lock Knob

  • Discrete lock and unlock positions and no blue line.

    • Delivery System (DS) Attach

  • Spring-loaded attachment slides into stabilizer rail. Replaces black screw.

    • Stabilizer

  • Stabilizer rail and handles to support the movement of the delivery system.

    • Guide Attach

  • Spring-loaded attachment with pins for insertion into stabilizer dock. Replaces black screws and the need to tighten screw to secure position.

    • Guide Attachment Braking System

  • Allows for adjustable guide positioning and holds guide catheter position. Replaces black screw.

    • Built-in DC Fastener

  • Rotation of fastener counterclockwise secures delivery catheter. Replaces black screw.

    • Test(s) performed by and data on file at Abbott.

    Easy Handling. Precise Positioning. Intuitive Deployment.

    The MitraClip G5 system is designed to support procedural control and efficiency in mitral valve repair. With thoughtfully integrated enhancements, the system facilitates connection, movement, and disconnection with minimal complexity. Key updates include refined attachment mechanisms and securement features, contributing to a more streamlined procedural experience.

    Learn more about the additional benefits of MitraClip TEER.

    • Broad range of sizes for tailored treatment8-11

      MitraClip TEER offers 4 Clip sizes to help tailor repair based on patient mitral valve anatomy.

      The NTW and XTW clips have a 50% wider grasping area than the NT and XT clips respectively. They are designed to further reduce regurgitant volume reduce MR with the implantation of a single clip.**

    • Treat more patients with more options8-11

      MitraClip successfully treats a broad range of valve anatomies in real world use8-11

      Significant and durable MR reduction achieved in patients with complex anatomies11

      90.3% of complex subjects achieved MR ≤1+ at 1 year.11

      Ability to choose clip size based on each MV anatomy8,10

      CLIP SELECTION CONSIDERATIONSFAVORS
      NTW      		FAVORS
      NT      		FAVORS
      XTW      		FAVORS
      XT
      Leaflet length < 9mm++  
      Leaflet length ≥ 9mm  ++
      Broad jet+ + 
      Smaller valve +  
      Larger valve+ ++

      MitraClip TEER clip selection recommendations were based on the initial clinical experience of an expert panel of physicians using the 4 Clip sizes of MitraClip G4.8,10 The implant device for the MitraClip G4 and the MitraClip G5 TEER Systems is identical.

      The EXPAND G4 real world study results further demonstrated clip selection preference and associated outcomes:10

      FOR PATIENTS WITH PMR

      XTW was used most often and achieved favorable MR reduction, particularly in patients with longer leaflets, large prolapse or wider jets, calcified leaflets or annulus and Barlow’s or bileaflet prolapse

      FOR PATIENTS WITH SMR

      NTW and XTW were used evenly across anatomies and achieved favorable MR reduction

      FOR ALL MR ETIOLOGIES

      NT and XT were used more frequently in multiple-clip cases and improved MR reduction

    • More options to confirm and optimize leaflet grasping with Controlled Gripper Actuation (CGA)1,**

      Controlled Gripper Actuation (CGA) provides the option to grasp leaflets simultaneously or independently, enabling the ability to confirm and optimize leaflet grasp.

      New gripper
      levers

      Simultaneous
      grasping

      MitraClip G4 CGA with simultaneous grasping

      Independant
      grasping

      MitraClip G4 CGA with independent grasping
    • Predictable procedure experience**

      The innovative Clip Delivery System is a highly maneuverable delivery catheter that is used to implant the MitraClip via a Steerable Guide Catheter.

      Precision and control from delivery system specifically designed for the mitral valve**
       

    MAT-2010221 v8.0 | Item approved for OUS use only.

    References

    **Tests performed by and data on file at Abbott.

    1. Data on File at Abbott.
    2. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association. Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Apr 01, 2022. Epublished DOI: 10.1016/j.jacc.2021.12.012
    3. Otto C, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Corrected version. Circ. 2021;143(5):e72-e227.
    4. McDonagh TA, Metra M, Adamo M, et al., ESC Scientific Document Group, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599–3726, doi.org/10.1093/eurheartj/ehab368
    5. Yeo KK, Tan JWC, Muller DW, et al. Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation. Eur Cardiol. 2021;16:e25. Published 2021 Jun 1. doi:10.15420/ecr.2021.01
    6. Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358-1365.
    7. Cioffi G, Tarantini L, De Feo S, et al. Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. Eur J Heart Fail. 2005;7(7):1112-1117.
    8. Von Bardeleben RS, Rogers J, Mahoney P, et al. Real-World Outcomes of Fourth-Generation Mitral Transcatheter Repair: 30-Day Results From EXPAND G4. J Am Coll Cardiol Intv. 2023 Jun, 16 (12) 1463-1473.
    9. Von Bardeleben RS, Mahoney P, Morse MA, et al. 1-Year Outcomes with Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair from the EXPAND G4 Study. J Am Coll Cardiol Intv. 2023 Nov. 16(21):2600-2610.
    10. Maisano F, Clip Selection Strategy with 4th Generation MitraClip™: Evidence-Based Recommendations from the Global EXPAND G4 Study. Data presented at PCR London Valve 2022.
    11. Rogers JH, et al. Expanding the Spectrum of TEER Suitability: Evidence from the EXPAND G4 Post Approval Study. JACC Cardiovasc Interv, 2023, 16(12): 1474-1485.
    12. Praz, et al., ESC/EACTS Guidelines for the management of valvular heart disease, European Heart Journal (2025) 00, 1-102, doi.org/10.1093/eurheartj/ehaf194
    Abbott Logo

    Follow Abbott

    Copyright © 2025 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
    Caution: Product(s) are intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at www.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
    Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
    Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
    No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

    MAT-2000631 v21.0 | Item approved for OUS use only.

    YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

    U.S. Health Care Professionals International Health Care Professionals

    YOU ARE ABOUT TO LEAVE
    www.structural­heart.abbott

    You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

    OkCancel
    +